United States - English - NLM (National Library of Medicine)

hahnemann laboratories, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) -

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale, and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any oth

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; hypromellose; polysorbate 80; pregelatinised maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate; polysorbate 80; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

United States - English - NLM (National Library of Medicine)

carilion materials management - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for suppressive treatment and for acute attacks of malaria due to and susceptible strains of the drug is also indicated for the treatment of extraintestinal amebiasis. p. vivax, p. malariae, p. ovale, p. falciparum. chloroquine phosphate tablets do not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum. use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to any other

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 250 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p. malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p.malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to a

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate 500 mg - chloroquine phosphate tablets are indicated for the suppressive treatment and for acute attacks of malaria due to p. vivax, p.malariae, p. ovale , and susceptible strains of p. falciparum. the drug is also indicated for the treatment of extraintestinal amebiasis. chloroquine phosphate tablets does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. it is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. in patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of p. falciparum . use of this drug is contraindicated in the presence of retinal or visual field changes either attributable to 4-aminoquinoline compounds or to a

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg - hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria: - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology: microbiology). hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets are